Globe Newswire

SoCal-based Clinical-Stage Biopharmaceutical Company Focused on Novel Therapeutics for Brain and Central Nervous System Diseases Nominated for Breakthrough Medical Technology Achievement Award

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage biopharmaceutical company, is proud to be presenting at the 2024 California Investment Forum (CIF), which will take place May 8-11 at the Anaheim Majestic Garden Hotel in Anaheim,... (continue reading...)

Recurring revenue represented 51% of total revenue and 72% of commercial revenue

First payments have been received for the Indonesian mapping program

Affirming 2024 projections of $16-18 million in revenue with EBITDA margin of approximately 25%

DENVER, May 09, 2024 (GLOBE NEWSWIRE) -- Intermap Technologies (TSX: IMP; OTCQB: ITMSF) (“Intermap” or the “Company”), a global leader in 3D geospatial products and intelligence solutions, today announced 42%... (continue reading...)

LISTING LINK : https://www.premiersothebysrealty.com/single-family/clm/car4128909/525-lake-lynn-road-concord-nc-28025

DROPBOX : https://www.dropbox.com/scl/fo/lg6584nf4vr1my9tw3ncf/APnG9lhA3o51-NMuToAMLDI?rlkey=g0ixv6rx4frcfk5fim13z5hy9&st=plszt1u7&dl=0

PHOTO CREDIT: Matthew Benham and Joseph Benham, Matthew Benham Photography

DALE EARNHARDT FILM: https://www.youtube.com/watch?v=PzmZmwGK_LI

CONCORD, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- The architectural... (continue reading...)

London, UK; Cambridge, MA, May 09, 2024 (GLOBE NEWSWIRE) -- Xtribe P.L.C. (“Xtribe”), a technology-driven platform that matches sellers of goods and services with local buyers, and WinVest Acquisition Corp. (“WinVest”) (NASDAQ: WINV), a publicly traded special purpose acquisition company, today announced that they have entered into a definitive business combination agreement (the “Business Combination Agreement”) with respect to a proposed business... (continue reading...)

–Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762

–Three patients have been enrolled

MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its Q1 2024 financial results and... (continue reading...)